Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results

Modern Pathology

Volumn 21, Issue 8, 2008, Pages 1037-1043

  Guo, Ming ^a   Lin, Ching Yu ^b   Gong, Yun ^a   Cogdell, David E ^a   Zhang, Wei ^a   Lin, E ^a   Sneige, Nour ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ASCUS; Genotyping; HPV; HSIL; Human papillomavirus; LSIL

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DNA VIRUS; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR VIRUS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA PROBES, HPV; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 48749109523     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.93     Document Type: Article

References (36)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079.
3. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
4. Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-355.
5. Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.
6. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.
7. Castle PE. The potential utility of HPV genotyping in screening and clinical management. J Natl Compr Canc Netw 2008;6:83-95.
8. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
9. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-1071.
10. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
11. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-105.
12. Guo M, Sneige N, Silva EG, et al. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol 2007;20:256-266.
13. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-517.
14. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
15. Gillio-Tos A, De Marco L, Ghisetti V, et al. Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. J Clin Virol 2006;36:126-132.
16. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-477.
17. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-795.
18. Lin CY, Chen HC, Lin RW, et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods 2007;140:1-9.
19. Huang LW, Chao SL, Chen PH, et al. Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 2004;29:271-276.
20. Zuna RE, Allen RA, Moore WE, et al. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 2007;20:167-174.
21. Wheeler CM, Hunt WC, Schiffman M, et al. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-1299.
22. Atkins KA, Jeronimo J, Stoler MH. Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer 2006;108:212-221.
23. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-10119.
24. Bulkmans NW, Berkhof J, Bulk S, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007;96:1419-1424.
25. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
26. Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24S3:S1-S10.
27. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
28. Naucler P, Ryd W, Tornberg S, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97:129-132.
29. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006;195:349-353.
30. Adams AL, Eltoum I, Roberson J, et al. Negative colposcopic biopsy after positive human papilloma virus (HPV) DNA testing: false-positive HPV results or false-negative histologic findings? Am J Clin Pathol 2006;125:413-418.
31. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
32. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-10636.
33. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597.
34. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772.
35. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356 e1-6.
36. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-1816.